BRIEF-Jazz Pharmaceuticals Q4 Adjusted EPS USD 6.6 Vs. IBES Estimate USD 5.81

Reuters

02-26

BRIEF-Jazz Pharmaceuticals Q4 Adjusted EPS USD 6.6 Vs. IBES Estimate USD 5.81

Feb 25 (Reuters) - Jazz Pharmaceuticals Q4 net income USD 191.115 million.

Q4 adjusted net income USD 405.863 million vs. IBES estimate USD 369.9 million
Q4 revenue USD 1,088.173 million vs. IBES estimate USD 1,060 million
Q4 EPS USD 3.11

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2514049067"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2514049067\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2514049067?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-26 05:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2514049067","market":"us","top_or_hot":-1,"title":"BRIEF-Jazz Pharmaceuticals Q4 Adjusted EPS USD 6.6 Vs. IBES Estimate USD 5.81","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\">\n<head>\n<meta/>\n<title>BRIEF-Jazz Pharmaceuticals Q4 Adjusted EPS USD 6.6 Vs. IBES Estimate USD 5.81</title>\n</head>\n<body>\n<p>Feb 25 (Reuters) - Jazz Pharmaceuticals Q4 net income USD 191.115 million.</p>\n<ul>\n<li>Q4 adjusted net income USD 405.863 million vs. IBES estimate USD 369.9 million</li>\n<li>Q4 revenue USD 1,088.173 million vs. IBES estimate USD 1,060 million</li>\n<li>Q4 EPS USD 3.11</li>\n</ul>\n</body>\n</html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Jazz Pharmaceuticals Q4 Adjusted EPS USD 6.6 Vs. IBES Estimate USD 5.81</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Jazz Pharmaceuticals Q4 Adjusted EPS USD 6.6 Vs. IBES Estimate USD 5.81\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-02-26 05:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\">\n<head>\n<meta/>\n<title>BRIEF-Jazz Pharmaceuticals Q4 Adjusted EPS USD 6.6 Vs. IBES Estimate USD 5.81</title>\n</head>\n<body>\n<p>Feb 25 (Reuters) - Jazz Pharmaceuticals Q4 net income USD 191.115 million.</p>\n<ul>\n<li>Q4 adjusted net income USD 405.863 million vs. IBES estimate USD 369.9 million</li>\n<li>Q4 revenue USD 1,088.173 million vs. IBES estimate USD 1,060 million</li>\n<li>Q4 EPS USD 3.11</li>\n</ul>\n</body>\n</html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JAZZ","symbol_name":"爵士制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nPLX6AFC90:1","article_id":"2514049067","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2514049067","pubTimestamp":1740517550,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Feb 25  - Jazz Pharmaceuticals Q4 net income USD 191.115 million.Q4 adjusted net income USD 405.863 million vs. IBES estimate USD 369.9 million. Q4 revenue USD 1,088.173 million vs. IBES estimate USD 1,060 million","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"JAZZ":"爵士制药"},"translate_title":"简介-Jazz Pharmaceuticals第四季度调整后每股收益为6.6美元，而IBES预估为5.81美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JAZZ":0.9},"content_text":"BRIEF-Jazz Pharmaceuticals Q4 Adjusted EPS USD 6.6 Vs. IBES Estimate USD 5.81\n\n\nFeb 25 (Reuters) - Jazz Pharmaceuticals Q4 net income USD 191.115 million.\n\nQ4 adjusted net income USD 405.863 million vs. IBES estimate USD 369.9 million\nQ4 revenue USD 1,088.173 million vs. IBES estimate USD 1,060 million\nQ4 EPS USD 3.11","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}